Data presented here confirm the positive therapeutic effects of rituximab on PAP lung with respect to enhanced alveolar macrophage functional activity and expression of lipid regulatory genes, PPARγ, ABCG1, and LPLA2. Here, PPARG is linked to pulmonary alveolar proteinosis.